None

FOPO nets $23.7mm for [AtriCure]

Cardiovascular device developer [AtriCure Inc.] has netted $23.7mm through the follow-on public offering of 3.5mm common shares at $7.25.

CEO of AtriCure leaves post

David Drachman has stepped down as president and CEO of AtriCure, but will remain with the cardiac ablation device firm throu -More- 

BRIEF-AtriCure falls 4.3 percent in extended trading

NEW YORK, Jan 15 (Reuters) - AtriCure Inc : * Shares fall 4.3 percent in extended trading

AtriCure's Frustratingly Slow Build Hides Value Beneath

By Stephen Simpson:Many investors like to believe that all a med-tech company has to do is develop a product for an under-served market, secure FDA approval, and then sit back and count the money as i...

AtriCure to Present at the Seventh Annual JMP Securities Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the excl...

AtriCure to Present at the Leerink Swann 2013 Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the excl...

AtriCure to Announce Third Quarter 2012 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release...

AtriCure to Announce Second Quarter 2012 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, will release...

None